Effect of acid inhibition on Campylobacter pylori
M Blanco1, J M Pajares, M L Jimenez
1Department of Internal Medicine-Gastroenterology, Autonoma University of Madrid, Hospital de la Princesa, Spain.
Abstract:
Campylobacter pylori (Cp) infection has been demonstrated in 59 of 65 (91%) patients with gastric or duodenal ulcer. Patients were included in a double blind study with ranitidine or famotidine for 4-8 weeks. After therapy, all gastric and duodenal ulcers healed but Cp remained in all previously infected patients, associated with chronic inflammation of gastric mucosa. Our results suggest that H2 antagonists do not have any effect either on Cp infection or on concurrent chronic gastritis. At the same time we observed that Cp infection does not disturb the ulcer healing process. However, Cp may be implicated in the persistence of the chronic gastritis and relapses of ulcers.
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Gastritis II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology


